Australia Bariatric Surgery Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia bariatric surgery market is being reshaped rather than displaced by weight-loss medicines. Procedure volumes face pressure from injectable therapies, yet severe obesity is widening, private hospital ownership is changing hands and device makers are bringing new staplers, robots and non-surgical options to Australian surgeons.

Three forces are shaping demand: a large and growing pool of eligible patients, with 13.0% of adults severely obese; a narrow public subsidy for semaglutide that leaves most people paying privately for medicines; and a concentrated private hospital sector, where Healthscope's restructuring is moving 25 hospitals to new owners.

In January 2026 Health Minister Mark Butler committed to listing Wegovy on the PBS for a narrow cardiovascular group, and in April 2026 Eli Lilly declined the government's price terms for Mounjaro in type 2 diabetes. In September 2026 a Calvary-led consortium agreed to buy Healthscope's remaining hospitals.

Key Market Trends and Insights

• Larger eligible population: The AIHW reported in June 2026 that 32.8% of Australian adults were obese and 13.0% severely obese, which keeps the pool of surgical candidates large.
• Narrow medicine subsidy: AAP reported in January 2026 that a PBS listing would cut Wegovy to $25 a script, but only for patients with cardiovascular disease and a BMI of 35 or more.
• Hospital ownership shift: A Calvary-led consortium agreed in September 2026 to take 25 Healthscope hospitals, with completion expected by 30 November 2026, protecting about 14,000 jobs.
• Funded national registry: The Bariatric Surgery Registry reported 20 new surgeons onboarded in 2025 and, in June 2026, two further years of Australian Government funding.

Australia Bariatric Surgery Market Size and Forecast

The market is moving from a sleeve-dominated, volume-led model towards a more selective mix of bypass, revision and technology-assisted procedures delivered to patients with higher disease burden. Sleeve gastrectomy leads in value, while one-anastomosis gastric bypass and endoscopic options advance fastest as surgeons and patients look for durable weight loss alongside medicines. Laparoscopic surgery remains the standard approach, and robotic assistance gains share as private hospitals invest in platforms. Private health insurance carries most of the cost, with self-funded patients growing as packages and finance options spread. New South Wales remains the largest region, and Queensland grows quickest on population growth and new private capacity. Registry funding, ownership change among hospital groups and cautious public subsidy of medicines point to a durable rebalancing of care pathways rather than a short cycle.

Key Takeaways: Australia Bariatric Surgery Market

Rising Disease Burden Anchors Long-Term Demand

Revenue is on course to expand by about 27% across the decade, from USD 295.00 million in 2025 to USD 373.96 million in 2035 at a 2.4% CAGR. The AIHW reported in June 2026 that 67.1% of adults were overweight or obese, and the bulk of treatment for severe disease remains surgical.

Bypass and Robotics Lead Growth

Sleeve Gastrectomy holds the largest share, but One-Anastomosis Gastric Bypass grows at an estimated 4.1% CAGR and Robotic-Assisted Surgery at an estimated 5.6% CAGR through 2035. Johnson & Johnson MedTech showed its ETHICON 4000 stapler to bariatric surgeons in June 2025, and the Registry reported robotic outcomes work in December 2025.

Medicine Subsidy Remains Narrow

The Pharmaceutical Benefits Advisory Committee recommended Wegovy in November 2025, yet access was described as slow and managed, so most patients still pay privately for medicines or consider surgery.

• Eligibility centres on cardiovascular disease with a BMI of 35 or more
• Eli Lilly declined Mounjaro price terms in April 2026
• More than 400,000 Australians pay privately for weight-loss medicines

Australia Bariatric Surgery Market Report Summary

Key Insight

Surgery remains the durable option for severe obesity. Sleeve procedures lead, bypass and robotic techniques grow fastest, and New South Wales leads while Queensland grows quickest.

Key Trends in the Australia Bariatric Surgery Market

The Australia bariatric surgery market is being reshaped by private hospital ownership change, medicine subsidy decisions, a rising national obesity burden and new technology for surgeons.

September 2026 - Calvary-Led Consortium Agrees to Buy Healthscope's Remaining Hospitals

• The Urban Developer reported on 28 September 2026 that Calvary will run 14 hospitals, Healthe Care six, Acurio Health three and KnG Group two.
• Completion is expected by 30 November 2026, subject to regulatory and lender approvals, ending a 16-month receivership.
• Clear owners for 25 private hospitals should stabilise theatre access for bariatric surgeons, who perform most operations in the private sector.

June 2026 - AIHW Reports 32.8% of Adults Obese and 13.0% Severely Obese

• The Australian Institute of Health and Welfare released its obesity report on 24 June 2026, finding 67.1% of adults overweight or obese.
• It estimated that AUD 800 million was spent treating obesity, and that overweight and obesity now contribute more to ill health than tobacco use.
• The widening severe-obesity group is the core addressable base for metabolic and bariatric operations.

April 2026 - Eli Lilly Declines Government Price Terms for Mounjaro in Type 2 Diabetes

• newsGP reported on 28 April 2026 that Lilly rejected the Pharmaceutical Benefits Advisory Committee recommendation, calling the proposed price unviable.
• Lilly said the outcome may impede future PBS submissions for other indications, such as obesity, and noted the drug costs up to $645 a month.
• Patients without subsidy face high medicine costs, which keeps surgery a competitive one-off option for suitable candidates.

January 2026 - Health Minister Commits to Wegovy PBS Listing for Cardiovascular Patients

• On 9 January 2026 Mark Butler said the government would list every Pharmaceutical Benefits Advisory Committee recommendation and negotiate prices with manufacturers.
• The committee, meeting in November 2025, recommended Wegovy for adults with cardiovascular disease and a BMI of 35 or more, with managed access.
• Most people living with obesity stay outside the criteria, so medicines are likely to widen the funnel for surgery as much as divert it.

Key Insight

Hospital ownership change, narrow medicine subsidies and a widening national obesity burden are the main structural forces, while medicine pricing decisions remain the main risk to surgical volume.

Recent Market Developments in the Australia Bariatric Surgery Market

Recent developments, presented from the most recent, show registry funding, a new non-surgical balloon, private hospital acquisition and new stapling technology for bariatric surgeons.

June 2026 - Bariatric Surgery Registry Secures Two Years of Government Funding

• The Registry's June 2026 newsletter said it had secured Australian Government funding for the next two years.
• It said the 2025 annual and individual surgeon reports were coming soon, and that adult patients receive a Registry flyer before surgery.
• Continued national outcome tracking supports surgeon benchmarking and helps hospitals and insurers judge procedure quality.

February 2026 - Allurion Wins FDA Decision for Swallowable Gastric Balloon System

• Allurion announced a decision on 23 February 2026 for its Gastric Balloon System, a swallowable capsule filled with fluid for about four months.
• In the 550-participant AUDACITY trial, 58% of treated patients lost more than 5% of body weight at 48 weeks.
• Allurion's balloon is already on the Australian Register of Therapeutic Goods, so a non-surgical option sits beside operations.

February 2026 - Ramsay Health Care Agrees to Acquire National Capital Private Hospital

• Healthscope's media release of 6 February 2026 said agreements were reached for Ramsay to take National Capital Private Hospital in Canberra.
• Calvary was to take Hobart Private and Holmesglen Private, and Mater Health was to take Gold Coast Private Hospital.
• Transfers to experienced operators should preserve elective surgery capacity, including bariatric lists, in the Australian Capital Territory, Tasmania, Victoria and Queensland.

December 2025 - Registry Reports 20 New Surgeons and Early Robotic Bariatric Outcomes

• The Bariatric Surgery Registry's December 2025 newsletter said it onboarded 20 new surgeons during 2025.
• It also listed two publications, including early outcomes of robotic bariatric surgery in Australia.
• A wider surgeon base and robotic evidence support gradual adoption of technology-assisted procedures.

Key Insight

Registry funding, hospital acquisitions and new device approvals show suppliers and hospital operators positioning for a more selective, technology-assisted surgical market through the forecast period.

Australia Bariatric Surgery Industry Segmentation

The Expert Market Research’s report on the Australia Bariatric Surgery Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Procedure Type

• Sleeve Gastrectomy
• Roux-en-Y Gastric Bypass
• One-Anastomosis Gastric Bypass
• Revision and Other Procedures
• Others

Sleeve Gastrectomy leads on value, in our estimate, because registry data show roughly four in five primary operations are sleeves, and it grows at an estimated 1.9% CAGR through 2035 as medicines compete for new patients. Roux-en-Y Gastric Bypass grows at 2.5%, favoured for reflux and diabetes. One-Anastomosis Gastric Bypass grows fastest at an estimated 4.1%, as surgeons adopt a shorter operation. Revision and Other Procedures, including balloons and endoscopic options such as Allurion's capsule decided by the FDA in February 2026, grow at 2.8%.

Market Breakup by Surgical Approach

• Laparoscopic Surgery
• Robotic-Assisted Surgery
• Endoscopic and Non-Surgical Interventions
• Open and Other Approaches
• Others

Laparoscopic Surgery leads, in our estimate, as most operations rely on staplers such as Johnson & Johnson MedTech's ETHICON 4000, shown to bariatric surgeons in June 2025. Robotic-Assisted Surgery grows fastest at an estimated 5.6% CAGR through 2035, backed by the Registry's December 2025 listing of early Australian robotic outcomes and Medtronic's Hugo platform, which gained FDA clearance in December 2025. Endoscopic and Non-Surgical Interventions grow at 3.8%, while Open and Other Approaches decline slightly at 0.4% and remain limited to complex revisions.

Market Breakup by Funding Source

• Private Health Insurance
• Self-Funded and Out-of-Pocket
• Public Hospital and Government Funding
• Others

Private Health Insurance leads, in our estimate, because registry data show about 95% of primary operations are privately funded and insurers contract with Healthscope, Ramsay and Calvary hospitals, whose ownership changed through 2026. Self-Funded and Out-of-Pocket grows fastest at an estimated 3.3% CAGR through 2035 as patients without cover or with exclusions pay directly, and as medicine costs reach up to $645 a month according to newsGP in April 2026. Public Hospital and Government Funding grows at 2.0%, held back by waiting lists and limited public theatre capacity.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• Others

New South Wales dominates, in our estimate, as the most populous state with the deepest private hospital base, and it grows at an estimated 2.1% CAGR through 2035 from a mature base. Victoria grows at 2.2%, with Healthscope's Holmesglen Private moving to Calvary. Queensland is the fastest-growing region at an estimated 3.1%, as Gold Coast Private Hospital transfers to Mater Health. Western Australia grows at 2.5%. Others, covering South Australia, Tasmania, the Australian Capital Territory and the Northern Territory, grow at 2.4%, including Ramsay's National Capital Private Hospital in Canberra.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Bariatric Surgery Market

Competition combines private hospital groups that host most operations, global device makers supplying staplers, robots and balloons, and surgeon-led practices. Entry barriers include theatre access, surgeon accreditation, registry participation, regulatory approval of devices and relationships with insurers.

Ramsay Health Care

Ramsay Health Care, headquartered in Sydney, operates private hospitals across Australia and lists bariatric surgery among its services, including at its national capital sites. Healthscope's media release of 6 February 2026 said agreements had been reached for Ramsay to acquire National Capital Private Hospital in Canberra. The addition extends its elective surgery footprint into a region with limited private capacity, where weight-loss operations form part of surgical lists.

Johnson & Johnson MedTech

Johnson & Johnson MedTech, based in New Brunswick, New Jersey, supplies Ethicon staplers, including the Echelon range listed on its Australian site. In June 2025 it launched the ETHICON 4000 stapler in the United States and showed it to bariatric surgeons at the ASMBS annual meeting. In April 2026 the device received a European CE Mark, and robotic integration with its OTTAVA system remains in development.

Medtronic

Medtronic, headquartered in Dublin, Ireland, supplies surgical stapling, energy devices and the Hugo robotic-assisted surgery system, which its Australian site lists for urologic, gynaecologic and general laparoscopic procedures. Medtronic received FDA clearance for Hugo in December 2025 and completed the first United States case in February 2026, with general surgery expansion planned. Hospital robotic investment may raise demand for compatible bariatric instruments in Australia.

Allurion

Allurion Technologies, based in Natick, Massachusetts, makes the Allurion Gastric Balloon, a swallowable capsule filled with fluid for about four months. The Australian Register of Therapeutic Goods lists the device as an active Class IIb gastric balloon for appetite suppression, sponsored by Emergo Australia. Allurion announced an FDA decision on 23 February 2026, supported by the AUDACITY trial of 550 participants, giving clinics a non-surgical entry option.

Other players operating in the Australia bariatric surgery market include Healthscope, Calvary Health Care, St Vincent's Health Australia, Mater Health, and Epworth HealthCare, alongside independent bariatric surgeons, day hospital operators, specialist clinics and smaller device distributors serving surgeons, hospitals and patients across Australia.

Key Insight

Competition rests on theatre access, surgeon accreditation, device approvals and insurer relationships rather than price alone, while ownership changes among hospital groups could reshape positions across the forecast period.